ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03184584
Recruitment Status : Enrolling by invitation
First Posted : June 12, 2017
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
ProMetic BioSciences Inc.

Brief Summary:
Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.

Condition or disease Intervention/treatment Phase
Alström Syndrome Drug: PBI-4050 Phase 2 Phase 3

Detailed Description:
This is a Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed the end-of-treatment (EoT) visit in a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050. This study will also evaluate the efficacy and pharmacological effects of PBI 4050 in this multi faceted disorder. Approximately 20 to 30 subjects will be enrolled to receive 800 mg PBI-4050 once daily for 96 weeks or until product licensing or study termination by the Sponsor, whichever occurs first.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Actual Study Start Date : October 9, 2017
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : September 2020


Arm Intervention/treatment
Experimental: PBI-4050 Drug: PBI-4050
Four 200 mg capsules (800 mg total) administered orally, once daily




Primary Outcome Measures :
  1. Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment [ Time Frame: 96 weeks ]

Secondary Outcome Measures :
  1. Change from baseline in fasting plasma glucose over time [ Time Frame: 96 weeks ]
  2. Change from baseline in plasma insulin over time [ Time Frame: 96 weeks ]
  3. Change from baseline in glycated hemoglobin (HbA1c) over time [ Time Frame: 96 weeks ]
  4. Change from baseline in blood glucose as measured by weekly 4 point profile [ Time Frame: 96 weeks ]
  5. Change from baseline in the liver stiffness [ Time Frame: 96 weeks ]
    Measured in kilopascal (kPa) correlated to fibrosis by using a FibroScan



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject completed a preceding ProMetic-sponsored Alström syndrome study with PBI-4050.
  • Subject has signed informed consent
  • Subject has a documented diagnosis of Alström syndrome
  • Subject receiving antidiabetic medications is able and willing to self-monitor blood glucose levels
  • Subject must be willing to forego other forms of experimental drug treatment during the study.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screening and agree to use adequate birth control from screening throughout the study and for 30 days after the last Investigational Medicinal Product (IMP) administration
  • If a male subject has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for 30 days after the last IMP administration.

Exclusion Criteria:

  • Subject discontinued PBI-4050 for safety reasons from any preceding ProMetic-sponsored Alström syndrome study with PBI-4050
  • Subject has had a documented episode of severe hypoglycaemia within 12 months before screening and investigator judges that the subject is unable to adequately monitor their glucose levels.
  • Subject has uncontrolled hypertension with BP > 170/100 mmHg as determined at screening.
  • Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study as determined at screening
  • Subject has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance
  • Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03184584


Locations
United Kingdom
University Hospitals Birmingham NHS Foundation Trus
Birmingham, United Kingdom, B15 2PR
Sponsors and Collaborators
ProMetic BioSciences Inc.

Responsible Party: ProMetic BioSciences Inc.
ClinicalTrials.gov Identifier: NCT03184584     History of Changes
Other Study ID Numbers: PBI-4050-CT-9-10
First Posted: June 12, 2017    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Syndrome
Alstrom Syndrome
Disease
Pathologic Processes
Hereditary Sensory and Motor Neuropathy
Nervous System Malformations
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Retinitis Pigmentosa
Eye Diseases, Hereditary
Eye Diseases
Ciliopathies
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn